Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Neumann, Inga D.
and
Landgraf, Rainer
2012.
Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors.
Trends in Neurosciences,
Vol. 35,
Issue. 11,
p.
649.
Montag, Christiane
Brockmann, Eva-Maria
Lehmann, Anja
Müller, Daniel J.
Rujescu, Dan
Gallinat, Jürgen
and
Reif, Andreas
2012.
Association between Oxytocin Receptor Gene Polymorphisms and Self-Rated ‘Empathic Concern’ in Schizophrenia.
PLoS ONE,
Vol. 7,
Issue. 12,
p.
e51882.
Stavropoulos, Katherine K. M.
and
Carver, Leslie J.
2013.
Research Review: Social motivation and oxytocin in autism – implications for joint attention development and intervention.
Journal of Child Psychology and Psychiatry,
Vol. 54,
Issue. 6,
p.
603.
Koh, Hae-Young
2013.
Phospholipase C-β1 and schizophrenia-related behaviors.
Advances in Biological Regulation,
Vol. 53,
Issue. 3,
p.
242.
Walss-Bass, Consuelo
Fernandes, João M.
Roberts, David L.
Service, Helena
and
Velligan, Dawn
2013.
Differential correlations between plasma oxytocin and social cognitive capacity and bias in schizophrenia.
Schizophrenia Research,
Vol. 147,
Issue. 2-3,
p.
387.
Ślusarz, Magdalena J.
Sikorska, Emilia
and
Ślusarz, Rafał
2013.
Interactions of vasopressin and oxytocin receptors with vasopressin analogues substituted in position 2 with 3,3′‐diphenylalanine – a molecular docking study.
Journal of Peptide Science,
Vol. 19,
Issue. 2,
p.
118.
Argiolas, Antonio
and
Melis, Maria Rosaria
2013.
Neuropeptides and central control of sexual behaviour from the past to the present: A review.
Progress in Neurobiology,
Vol. 108,
Issue. ,
p.
80.
Seeman, Mary V
2013.
Women and schizophrenia: new findings.
Neuropsychiatry,
Vol. 3,
Issue. 4,
p.
423.
Janicak, Philip G.
2013.
Novel Approaches for Managing Schizophrenia.
Psychopharm Review,
Vol. 48,
Issue. 9,
p.
65.
Cochran, David M.
Fallon, Daniel
Hill, Michael
and
Frazier, Jean A.
2013.
The Role of Oxytocin in Psychiatric Disorders.
Harvard Review of Psychiatry,
Vol. 21,
Issue. 5,
p.
219.
Stevens, Francis L.
Wiesman, Omri
Feldman, Ruth
Hurley, Robin A.
and
Taber, Katherine H.
2013.
Oxytocin and Behavior: Evidence for Effects in the Brain.
The Journal of Neuropsychiatry and Clinical Neurosciences,
Vol. 25,
Issue. 2,
p.
96.
de Lacy, Nina
and
King, Bryan H.
2013.
Revisiting the Relationship Between Autism and Schizophrenia: Toward an Integrated Neurobiology.
Annual Review of Clinical Psychology,
Vol. 9,
Issue. 1,
p.
555.
Janicak, Philip G.
2014.
Schizophrenia.
p.
107.
Seay, Julia S.
Lattie, Emily
Schneiderman, Neil
Antoni, Michael H.
Fekete, Erin M.
Mendez, Armando J.
Szeto, Angela
and
Fletcher, Mary Ann
2014.
Linear and Quadratic Associations of Plasma Oxytocin With Depressive Symptoms in Ethnic Minority Women Living With HIV.
Journal of Applied Biobehavioral Research,
Vol. 19,
Issue. 1,
p.
70.
Imanieh, Mohammad Hossein
Bagheri, Fereshte
Alizadeh, Ali Mohammad
and
Ashkani-Esfahani, Soheil
2014.
Oxytocin has therapeutic effects on cancer, a hypothesis.
European Journal of Pharmacology,
Vol. 741,
Issue. ,
p.
112.
Javitt, Daniel C.
2014.
Current and Emergent Treatments for Symptoms and Neurocognitive Impairment in Schizophrenia.
Current Treatment Options in Psychiatry,
Vol. 1,
Issue. 2,
p.
107.
Gannon, Robert L.
2014.
Non-peptide oxytocin receptor ligands and hamster circadian wheel running rhythms.
Brain Research,
Vol. 1585,
Issue. ,
p.
184.
Feifel, David
and
MacDonald, Kai
2014.
Encyclopedia of Psychopharmacology.
p.
1.
Pedersen, Cort A.
2014.
Schizophrenia and alcohol dependence: Diverse clinical effects of oxytocin and their evolutionary origins.
Brain Research,
Vol. 1580,
Issue. ,
p.
102.
Hosseini, Seyed Mohammad Reza
Farokhnia, Mehdi
Rezaei, Farzin
Gougol, Amirhossein
Yekehtaz, Habibeh
Iranpour, Negar
Salehi, Bahman
Tabrizi, Mina
Tajdini, Masih
Ghaleiha, Ali
and
Akhondzadeh, Shahin
2014.
Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: A randomized, double-blind, placebo-controlled, clinical trial.
European Neuropsychopharmacology,
Vol. 24,
Issue. 6,
p.
846.